David Sebag-Montefiore: Fantastic that the Cancer Research UK’s Stand Up To Cancer funded PLATO anal cancer trials platform has completed recruitment of 709 patients- a great achievement in a rare disease.
Quoting David Sebag-Montefiore, Director at Leeds Cancer Research Centre, on LinkedIn:
“Fantastic that the Cancer Research UK‘s Stand Up To Cancer funded PLATO (Platelet Inhibition and Patient Outcomes) anal cancer trials platform has completed recruitment of 709 patients – a great achievement in a rare disease.
A huge thank you to our 40 recruiting sites across the UK, the clinical trial team, our collaborators across the UK, our oversight committees, our funders, and most importantly the patients who have taken part!
The innovative “team science” trial platform hosted by Leeds Clinical Trials Research Unit includes three trials ACT3, 4 and 5 testing radiotherapy dose de-escalation and dose escalation and a Cancer Research UK (CRUK) discovery/translational biomarker award ensuring we learn as much as we can from our clinical trial patients.
The initial results of ACT4 using dose de-escalation are exciting with future reports including the primary outcomes of all three trials to follow!”
Source: David Sebag-Montefiore/LinkedIn